High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

Ryoko Mabuchi, Takeshi Hara, Takuro Matsumoto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Masahito Shimizu, Hiroyasu Ito, Yasuko Yamamoto, Kuniaki Saito, Hisataka Moriwaki, Hisashi Tsurumi

研究成果: Article査読

21 被引用数 (Scopus)

抄録

The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and ≥ 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.

本文言語English
ページ(範囲)92-98
ページ数7
ジャーナルLeukemia and Lymphoma
57
1
DOI
出版ステータスPublished - 02-01-2016

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

フィンガープリント 「High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル